BackgroundGastric cancer (GC) is the fifth commonest cancer and the third commonest reason of death causing by cancer worldwide. Currently, tumor immunology and ferropotosis develop rapidly that has made gastric cancer be treated in new directions. So, finding the potential targets and prognostic biomarkers for immunotherapy combined with ferropotosis is urgent. MethodsBy mining TCGA, immune-related genes, ferropotosis-related genes and immune-ferropotosis-related differentially expressed genes (IFR-DEGs) were identified. The independent prognostic value of IFR-DEGs was determined by differential expression analysis, prognostic analysis, and univariate and lasso regression analysis. Then, based on the prognostic risk model, the correlation between IFR-DEGs and immune scores, immune checkpoints were evaluated. Besides, we predicted the response of high and low risk groups to drugs. ResultsA 15-gene prognostic feature was constructed. The high-risk group had a poorer prognosis than the low-risk group. High-risk group had higher level of Treg immune cell infiltration compared with that in the low-risk group, and the tumor purity, immune checkpoint PD-1 and CTLA4, and immunity in the high-risk group were higher than those in the low-risk group. These results indicate that immune ferropotosis-related genes migh be potential predictors of STAD's response to ICI immunotherapy biomarkers. In addition, the response of small molecule drugs such as Nilotini, Sunitinib, Imatinib, etc. for high and low risk groups was predicted. ConclusionIFRSig can be regarded as an independent prognostic feature and may estimate OS and clinical treatment response in patients with STAD. IFRSig also has important correlation with immune microenvironment. A new understanding of the immune-ferropotosis-related genes during the occurrence and development of STAD is provided in this study.

This study is to investigate the effects of brucea javanica oil emulsion (BJOE) combined with transcatheter hepatic arterial chemoembolization (TACE) on primary liver cancer (PLC) and the related mechanisms. Totally 64 PLC patients were divided into the TACE monotherapy and BJOE/TACE combination therapy groups. The short- and long-term efficacies, and the toxicity and tolerability profiles, of these treatments were evaluated. The serum levels of soluble Fas (sFas) and soluble Fas ligand (sFasL) were detected with ELISA. For the short-term efficacy, the response rate (RR) in the TACE monotherapy and BJOE/TACE combination therapy groups were 50% (16/32) and 78.12% (25/32), respectively. Survival analysis showed that, the combination therapy significantly elevated the 1-, 2-, and 3-year survival rates of PLC patients, compared with the monotherapy. No significant differences were observed in the toxicity and tolerability profiles between these therapies. ELISA showed that, the serum sFas/sFasL levels were significantly increased in PLC patients. At 1 m after the combination therapy, the serum sFas/sFasL levels were significantly higher than before treatment. At 3 m and 6 m after treatment, the serum sFas/sFasL levels were gradually declined. The short- and long-term efficacies of the BJOE/TACE combination therapy for PLC are superior to the TACE monotherapy. The combination therapy could promote liver cancer cell apoptosis by regulating the expression of sFas/sFasL. Serum sFas/sFasL levels might be used as the predictive marker for the disease pathogenesis and prognosis, and the treatment efficacy.

Objective To study the changes of the plasma thrombomodulin (TM) and von Willebrand factor (vWF) levels and their clinical significance associated with the extent and severity of acute ischemie colitis.Methods The plasma TM and vWF levels were determined by enzyme linked immunosorbent assay in 46 patients with acute ischemic colitis (acute ischemic colitis group),42 patients with ulcerative colitis (ulcerative colitis group) and 40 healthy subjects (control group).Results The plasma TM was (49.6 ±2.3) μg/L,and vWF was (198.8 ±8.9)％ in acute ischemic colitis group.The plasma TM was (38.2 ± 3.8) μ g/L,and vWF was ( 162.6 ± 7.6)％ in ulcerative colitis group.The plasma TM was (23.8 ±2.3) μg/L,and vWF was ( 116.7 ± 6.2)％ in control group.The plasma TM and vWF levels in acute ischemic colitis group were higher than those in ulcerative colitis group and control group (P ＜ 0.05 or ＜ 0.01 ).The plasma TM and vWF levels in ulcerative colitis group were higher than those in control group (P＜ 0.05).The plasma TM levels [(49.9 ± 0.3 ) μg/L] and vWF [(210.6 ± 8.2 ) ％] in all colon disease were higher than those in partial colon disease (P ＜ 0.05 ).Conclusion The changes of plasma TM and vWF levels can be used as one of the indicators for assessment of the development and the prognosis of acute ischemic colitis.

目的:为了降低PAE对亚胺培南的耐药率,以提高临床的抗感染治疗效果,并尽力减少多药耐药的菌株的产生.方法:采用法国梅里埃全自动细菌分析系统检测11株PAE抗菌药物情况.结论:抗菌药物的药敏鉴定为临床用药提供了必要的辅助作用.

Objective To detect class 1~3 integrons in Acinetobacter baumanii and analyze influence of integrons on multidrug resistance. Methods The drug resistance of 68 strains of Acinetobacter baumanii isolated from clinical to 24 antibacterials was determined by the agar two-fold dilution method. Strains with integrons were preliminarily screened by polymerase chain reaction and then classified by RAPD(random amplified polymorphic DNA).Results It was found that incidence of class 1 integron(intI) were 27.9% and no class 2,3 integron detected among 68 strains of Acinetobacter baumanii. The intI-positive strains show high resistance to penicillins, cephalosporins, aminoglycosides and tetracyclines, with the incidence rate of drug resistance from 86.7% to 100%, and 100% to the third generation of cephalosporins and 82.5% to β-lactamases inhibitor combinations.The difference of the rate of drug resistance to aminoglycosides and sulfamide between intI-positive strains and intI-negative strains were statistically significant.Conclusion Class 1 integron was extensively found in Acinetobacter baumaniis, and integrons play a important role in multidrug resistance.

目的比较哌拉西林/舒巴坦与其他4种β-内酰胺类抗菌药物对临床分离菌的体外抗菌活性。方法采用琼脂平板二倍稀释法测定对151株临床分离菌株的最低抑菌浓度。结果哌拉西林/舒巴坦对革兰阳性菌和革兰阴性菌均有较好的抗菌活性。铜绿假单胞菌属、不动杆菌属、肠球菌属对哌拉西林/舒巴坦的敏感性最高,敏感率均为100%,大肠埃希菌、肺炎克雷伯菌、葡萄球菌属对哌拉西林/舒巴坦的敏感性较高,敏感率为80.00%~93.74%。大肠埃希菌、肺炎克雷伯菌、葡萄球菌属、铜绿假单胞菌属、不动杆菌属对两种哌拉西林酶抑制剂复方制剂均比较敏感。结论哌拉西林/舒巴坦与哌拉西林比较,有较强的抗药活性。

OBJECTIVE: To investigate the resistance phenotype of acinetobacter baumannii and the expression of ade efflux pump gene. METHODS: Non-repetitive 51 strains of Acinetobacter baumannii were collected in Peking Union Medical Hospital between Feb. 2004 and Feb. 2005. The active efflux system adeB structural gene and sequence were identified by PCR. RESULTS: The tested strains were not susceptible to common broad-spectrum antibiotics. Multidrug resistant Acinetobacter baumannii carried adeB active efflux pump gene. CONCLUSION: The multiple-drug resistance of Acinetobacter baumannii is independent of β-lactamase. It maybe related to other drug resistance mechanism. The effect of active efflux system is possibly one of the major mechanisms of multidrug resistance of acinetobacter baumannii.

对米卡芬净的作用机制、抗菌谱、药动学、药物相互作用、临床疗效有效性和安全性评价以及不良反应和耐受性的有关研究进行了综述。

卡氏肺孢子虫肺炎(pneumocystis carinii pneumonia,PCP) 是人畜共患的机会性感染性疾病.其病原体卡氏肺孢子虫(pneumocystis carinii,PC)是由Chagas于1909年从豚鼠肺中发现的,可寄生于人和其它哺乳动物肺组织中.免疫功能低下者(如艾滋病、器官移植、白血病、恶性肿瘤患者等)易致病,一旦感染难以控制.